medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
medical device investing HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
medical device investing HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
medical device investing Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Contakt World Provides Company Update as it Continues to Expand its Portfolio of SaaS Solutions and Commercial Presence in the US Market
Contakt World Expands Commercial Portfolio Through Partnership Agreement with Portum for Health Screening, Vaccine Wallet, Vaccine Passport, and More
Contakt World Launches Sales Representative Program to Continue to Grow Revenue for Its Cash Flow Positive HealthCheck Screening Tool and Vaccine Passport Solution
Contakt World to Offer Vaccine Passport and Verification Platform To Employers, Events and Organizations, Including Customers of Recently Acquired HealthCheck App
